Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters
J. W. Koskenvuo, J. J. Hartiala, P. Nuutila, R. Kalliokoski, J. S. Viikari, E. Engblom, M. Penttinen, J. Knuuti, I. Mononen, I. M. KantolaVolume:
31
Language:
english
Pages:
10
DOI:
10.1007/s10545-008-0848-3
Date:
June, 2008
File:
PDF, 339 KB
english, 2008